In fact, declines in MCL-1 have been achieved via ibrutinib treatment followed by venetoclax treatment; this combination therapy appears to be successful in CLL (200, 201) and MCL. This evidence concerns the gene MCL1 and B-cell chronic lymphocytic leukemia.